EpCAM-expressing circulating tumor cells in colorectal cancer

Chiara Nicolazzo, Cristina Raimondi, Federica Francescangeli, Simona Ceccarelli, Patrizia Trenta, Valentina Magri, Cinzia Marchese, Ann Zeuner, Angela Gradilone, Paola Gazzaniga
DOI: 10.5301/ijbm.5000284
PMID: 28604994

Abstract

Background: Several studies have raised the issue of the inadequacy of CellSearch® to detect the entire pool of circulating tumor cells (CTCs) from blood of cancer patients, suggesting that cells expressing low levels of epithelial cell adhesion molecule (EpCAM) are not recognized by the capture reagent. In this exploratory study, we aimed to evaluate the status of EpCAM in CTCs isolated from a group of metastatic colorectal cancer patients, in 40% of whom, CTC had been found to be undetected by the CellSearch® system. Methods: CTCs were analyzed using both a microfiltration method (ScreenCell) and CellSearch® in parallel. Furthermore, since EpCAM exists in 2 different variants, we investigated the presence of both its intracellular domain (EpICD) and extracellular domain (EpEX) through immunofluorescence staining of CTCs on filters. Results: Results from immunofluorescence experiments demonstrated that, overall, EpICD and/or EpEX was expressed in 176 CTCs detected by ScreenCell, while the CellSearch® system was able to capture only 10 CTCs. Conclusions: This is the first demonstration that the low sensitivity of CellSearch® to detect CTCs in colorectal cancer patients is not due to the lack of EpCAM. »

Mots clés

CellSearch®, Circulating tumor cells, Colorectal cancer, EpCAM, Liquid biopsy, ScreenCell

Restez informé de nos publications

Dernières publications

Isolation and profiling of single circulating tumor cells in myeloma: a new workflow for liquid biopsies.

Liquid biopsy in breast cancer: Redefining precision medicine

Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical Applications

Un projet sur les cellules tumorales circulantes ?

De l'isolement des CTC aux analyses en aval, ScreenCell® s'adapte à chaque étape.

Suivez ScreenCell sur LinkedIn